Genmab A/S
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Jan van de Winkel
- Full Time Employees
- 3,119
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Carl Jacobsens Vej 30 Copenhagen CD Denmark 2500
- IPO Date
- Jun 1, 2009
- CIK
- 0001434265
- Website
- genmab.com
- Similar Companies
- Business
- Genmab A/S develops differentiated antibody therapeutics targeting cancer and other serious diseases using proprietary platforms including DuoBody, HexaBody, UniBody and HuMab-Mouse technologies; core products encompass approved medicines such as EPKINLY (epcoritamab, a CD3xCD20 bispecific T-cell engager for relapsed/refractory diffuse large B-cell lymphoma marketed with AbbVie), TIVDAK (tisotumab vedotin, a tissue factor-directed antibody-drug conjugate for recurrent/metastatic cervical cancer marketed with Seagen), royalties from partner-marketed DARZALEX (daratumumab for multiple myeloma and AL amyloidosis by Janssen), Kesimpta (ofatumumab for relapsing remitting multiple sclerosis by Novartis), RYBREVANT (amivantamab for non-small cell lung cancer by Janssen), TECVAYLI and TALVEY (teclistamab and talquetamab bispecifics for relapsed/refractory multiple myeloma by Janssen) and TEPEZZA (teprotumumab for thyroid eye disease by Horizon); the company advances a broad pipeline of proprietary and partnered bispecific antibodies, antibody-drug conjugates and immune checkpoint modulators in oncology and autoimmune indications. Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab operates globally through subsidiaries in the Netherlands, United States, Japan, Germany and China, serving pharmaceutical partners and patients across North America, Europe and Asia Pacific. Recent developments include the 2024 acquisition of ProfoundBio for $1.8 billion to bolster its antibody-drug conjugate capabilities (with subsequent discontinuation of certain assets), the September 2025 announcement of an $8 billion acquisition of Merus to integrate petosemtamab (a late-stage bispecific for head and neck cancer) and accelerate transition to a wholly owned model, successful independent launches and international expansions of EPKINLY and TIVDAK in Europe and Japan, and positive Phase III data for epcoritamab expansions plus Rina-S programs driving projected double-digit revenue growth to $3.5-3.7 billion in 2025.
Company News
Critical Analysis: Genmab A/S (NASDAQ:GMAB) versus Cardio Diagnostics (NASDAQ:CDIO)
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026
Resolution Adopted at the Extraordinary General Meeting of Genmab A/S Including Grant of Restricted Stock Units to Board Members
Genmab: Epkinly Shines In Phase 3 DLBCL Trial
AbbVie's Epcoritamab Combo Shows PFS Benefit in Frontline DLBCL
Strength Seen in Genmab (GMAB): Can Its 10.7% Jump Turn into More Strength?
Genmab Shares Climb After Positive Study Results for Blood-Cancer Drug
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer
Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4
Genmab A/S (NASDAQ:GMAB) Hits New 1-Year High – What’s Next?
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Genmab A/S (GMAB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Capital Increase in Genmab as a Result of Employee Warrant Exercise